title: [A case of recurrent colon cancer developed thrombosis in superior mesenteric vein after chemotherapy].
abstract: A 48-year-old man was administered bevacizumab+FOLFOX for lymph node recurrence of colon cancer in the abdominal cavity, and developed serious thrombosis of the portal system after 6 courses of the chemotherapy. We discontinued it promptly and anticoagulant therapy with urokinase was started immediately, but a complete dissolution was not achieved. Preservation therapy using anticoagulants for a long duration was effective for controling the of clinical symptom of thrombosis. The result of 6 courses of chemotherapy was CR, and the effect continues today, without further treatment 2 years later.
authors.affiliation: Dept. of Surgery, Tenri Hospital, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Furuyama
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Fuji
authors.forename: Shinya
authors.initials: S
authors.lastname: Okumura
authors.forename: Tatsuhito
authors.initials: T
authors.lastname: Nishigori
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Kadokawa
authors.forename: Masato
authors.initials: M
authors.lastname: Kondo
authors.forename: Takafumi
authors.initials: T
authors.lastname: Machimoto
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Asao
authors.forename: Tsunehiro
authors.initials: T
authors.lastname: Yoshimura
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008642:Mesenteric Veins / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005343:Fibrinolytic Agents; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D014568:Urokinase-Type Plasminogen Activator; D002955:Leucovorin; D005472:Fluorouracil